A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

Exclusion Criteria

• •Have any clinically relevant abnormality identified on the screening history and physical or laboratory examination, 12-lead surface electrocardiogram (ECG) and/or 24 hour Holter, including QTc \> 450 msec
• •Test positive urine drug screen or alcohol
• •Test positive for HIV, hepatitis B virus or hepatitis C virus
• •Smoker or have a history of smoking or use of nicotine containing products within one year of the study or \>10 pack-year history of smoking overall
• •have a history of regular alcohol consumption exceeding 7 units/week (1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
• •have a history of drug abuse within 6 months of the study
• •have participated in a trial with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
• •use of prescription or non-prescription drugs (including calcium tablets, calcium containing antacids, aspirin or nonsteroidal anti-inflammatory drugs), vitamins, herbal and dietary supplements, within 14 days prior to the first dose of study medication.
• •have consumed of grapefruit containing products within 14 days prior to the first dose of study medication
• •have donated of blood in excess of 500 mL within 56 days prior to dosing
• •have evidence of kidney or liver disease
• •have a history of significant gastrointestinal disease or a gastrointestinal surgical procedures
• •are sensitive to any of the study medications or components thereof
• •have a history of cardiovascular disease
• •have medical conditions which might alter bone metabolism
• •have a serum parathyroid hormone (iPTH) test, or vitamin D levels outside the normal range